B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20

Michael Levy; Maureen A Mealy

doi:10.2147/ITT.S255722

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20

Immunotargets Ther. 2021 Aug 20:10:325-331. doi: 10.2147/ITT.S255722. eCollection 2021.

Authors

Michael Levy¹, Maureen A Mealy²

Affiliations

¹ Department of Neurology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
² Medical Affairs, Horizon Therapeutics, Deerfield, IL, USA.

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system that preferentially targets the optic nerves and spinal cord, leading to visual loss and impaired mobility. Until 2019, no medications were FDA-approved for NMOSD treatment, and standard of care was based on mostly empiric and retrospective data. Therapies that target B cells emerged as a treatment strategy due to their fundamental role in disease pathogenesis. We explore different monoclonal antibodies directed at either CD20+ or CD19+ B cells that may have utilization in the treatment of NMOSD, discussing what is known regarding their efficacy and safety.

Keywords: MOG; NMO; inebilizumab; monoclonal; rituximab.

Publication types

Review